CCM
CABA icon

CAAS Capital Management’s Cabaletta Bio CABA Stock Holding History

CAAS Capital Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-147,382
Closed -$1.64M – 1063
2021
Q1 		$1.64M Buy
+147,382
New +$1.8M 0.02% 650

Other funds holding CABA

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CAAS Capital Management's CABA Position: Q2 2021 in Review

CAAS Capital Management sold out of Cabaletta Bio (CABA) in Q2 2021, closing a stake of 147,382 shares — an estimated $1.64M sold.

CAAS Capital Management first reported a position in CABA in Q1 2021 and held it in 1 quarter. The position peaked at $1.64M in Q1 2021. 63 funds tracked by Wall St. Rank hold CABA as of Q2 2021.

  • CAAS Capital Management reported no remaining Cabaletta Bio position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 147,382 Cabaletta Bio shares in Q2 2021, an estimated $1.64M.
  • CAAS Capital Management first reported a position in Cabaletta Bio in Q1 2021 and held it in 1 quarter.
  • CAAS Capital Management's Cabaletta Bio position peaked at $1.64M in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.